⌘K
t
Nuformix plc announced on 29 April 2025 that it has changed its registered office to C/O Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ. This change took effect immediately. Additionally, the Board appointed Shaun Zulafqar as Company Secretary, effective immediately.
| Date | 29 Apr 2025 |
| Time | 07:00:08 |
| Category | Corporate updates |
| ID | 5101G |
29 April 2025
Nuformix plc
("Nuformix" or the "Company")
Change of Registered Office and appointment of Company Secretary
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has changed its registered office to C/O Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ with immediate effect.
The Board is also pleased to announce that it has appointed Shaun Zulafqar as Company Secretary with immediate effect.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory
|
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
|
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.